neuroprotection
(3)
Scott Greenberg
Scott Greenberg is the Chief Business Officer of Nura Bio, a clinical-stage biopharmaceutical company in South San Francisco building small-molecule drugs to stop nerves from dying. He joined in February 2025 to steer business development and corporate strategy as the company pushes its lead SARM1 inhibitor, NB-4746, into the clinic. He arrives with more than two decades crossing the line between finance and biology - a Goldman Sachs banking start, more than a decade at Celgene, an operations leadership role at Roivant Sciences, and a stint as Chief Operating Officer at Aro Biotherapeutics. He studied both Finance and the Biological Basis of Behavior at the University of Pennsylvania before an MBA at Harvard.
Larry Brown
Larry Brown, Sc.D., is Executive Vice President of R&D and Chief Scientific Officer at Noveome Biotherapeutics, the Pittsburgh clinical-stage biopharma he joined in 2012. He is leading the translation of ST266, a cell-free secretome of hundreds of proteins harvested from amnion-derived cells, from proof of principle into the clinic. Trained at MIT under Robert Langer and in Judah Folkman's surgical research lab at Children's Hospital Boston, he spent 35-plus years inventing drug-delivery systems at Baxter, Alkermes and biotech startups, accumulating more than 100 publications and a thick stack of patents along the way.
Shilpa Sambashivan
Shilpa Sambashivan is the CEO and a co-founder of Nura Bio, a South San Francisco biotech building brain-penetrant small molecules that aim to stop nerves from dying. A protein biochemist by training, she helped spin the company out of academic labs in 2018, built its R&D engine as Chief Scientific Officer, and was elevated to CEO in September 2024 alongside a $68M Series A extension that pushed total funding past $140M. Her lead drug, NB-4746, blocks the SARM1 enzyme that triggers axon self-destruction.